AAC
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Goldstein, E. J. C.
Right arrow Articles by Tyrrell, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Goldstein, E. J. C.
Right arrow Articles by Tyrrell, K.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, September 2000, p. 2525-2529, Vol. 44, No. 9
0066-4804/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.

Comparative In Vitro Activities of ABT-773 against Aerobic and Anaerobic Pathogens Isolated from Skin and Soft-Tissue Animal and Human Bite Wound Infections

Ellie J. C. Goldstein,1,2,* Diane M. Citron,1 C. Vreni Merriam,1 Yumi Warren,1 and Kerin Tyrrell1

R. M. Alden Research Laboratory, Santa Monica-University of California at Los Angeles Medical Center, Santa Monica, California 90404,1 and School of Medicine, University of California at Los Angeles, Los Angeles, California 900732

Received 14 February 2000/Returned for modification 14 May 2000/Accepted 12 June 2000

We studied the comparative in vitro activities of ABT-773, a new ketolide, against 268 aerobic and 148 anaerobic recent isolates from clinical bites using an agar dilution method and inocula of 104 CFU/spot for aerobes and 105 CFU for anaerobes. The following are the MIC ranges and MICs at which 90% of isolates are inhibited (MIC90s) of ABT-773 for various isolates, respectively: Pasteurella multocida and Pasteurella septica, 0.125 to 2 and 1 µg/ml; other Pasteurella species, 0.125 to 1 and 0.5 µg/ml; Corynebacterium spp., 0.015 to 0.06 and 0.015 µg/ml; Staphylococcus aureus, 0.03 to 0.06 and 0.06 µg/ml; coagulase-negative staphylococci, 0.015 to >32 and 32 µg/ml; streptococci, 0.015 to 0.03 and 0.03 µg/ml; Eikenella corrodens, 0.25 to 1 and 1 µg/ml; and Bergeyella zoohelcum, 0.03 to 0.25 and 0.06 µg/ml. For anaerobes the MIC ranges and MIC90s of ABT-773 were as follows, respectively: Prevotella heparinolytica, 0.06 to 0.125 and 0.125 µg/ml; Prevotella spp., 0.015 to 0.125 and 0.06 µg/ml; Porphyromonas spp., 0.015 to 0.03 and 0.015 µg/ml; Fusobacterium nucleatum, 0.5 to 8 and 8 µg/ml; other Fusobacterium spp., 0.015 to 8 and 0.5 µg/ml; Bacteroides tectum, 0.015 to 0.5 and 0.06 µg/ml; and Peptostreptococcus spp., 0.015 to 0.25 and 0.03 µg/ml. ABT-773 was more active than all macrolides tested against S. aureus, E. corrodens, and anaerobes, but all compounds were poorly active against F. nucleatum. The activity of ABT-773 was within 1 dilution of that of azithromycin against Pasteurella spp., and ABT-773 was four- to eightfold more active than clarithromycin against Pasteurella spp. ABT-773 may offer a therapeutic alternative for bite wound infections.

* Corresponding author. Mailing address: 2021 Santa Monica Blvd., Suite 640 East, Santa Monica, CA 90404. Phone: (310) 315-1511. Fax: (310) 315-3662. E-mail: EJCGMD{at}aol.com.

Antimicrobial Agents and Chemotherapy, September 2000, p. 2525-2529, Vol. 44, No. 9
0066-4804/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:



Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Clin. Vaccine Immunol. Clin. Microbiol. Rev.
J. Clin. Microbiol. ALL ASM JOURNALS

Copyright © 2000 by the American Society for Microbiology. All rights reserved.